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ABSTRACT
4-Hydroxy-2-nonenal (HNE) is a reactive  ,-
unsaturated aldehyde generated during oxidative
stress and subsequent peroxidation of polyunsatu-
rated fatty acids. Here, Werner protein (WRN) was
identified as a novel target for modification by HNE.
Werner syndrome arises through mutations in the
WRN gene that encodes the RecQ DNA helicase
which is critical for maintaining genomic stability.
This hereditary disease is associated with chromo-
somal instability, premature aging and cancer predis-
position. WRN appears to participate in the cellular
response to oxidative stress and cells devoid of WRN
display elevated levels of oxidative DNA damage.
We demonstrated that helicase/ATPase and exonu-
clease activities of HNE-modified WRN protein were
inhibited both in vitro and in immunocomplexes pu-
rified from the cell extracts. Sites of HNE adduction
in human WRN were identified at Lys577, Cys727,
His1290, Cys1367, Lys1371 and Lys1389. We applied
in silico modeling of the helicase and RQC domains
of WRN protein with HNE adducted to Lys577 and
Cys727 and provided a potential mechanism of the
observed deregulation of the protein catalytic activ-
ities. In light of the obtained results, we postulate
that HNE adduction to WRN is a post-translational
modification, which may affect WRN conformational
stability and function, contributing to features and
diseases associated with premature senescence.
INTRODUCTION
Werner syndrome (WS) is a rare human autosomal, reces-
sive disease that results in premature aging. WS cases are
characterized by numerous progeroid pathologies includ-
ing osteoporosis, atherosclerosis, type II diabetes, cataracts
and a marked increase in the incidence of cancer, particu-
larly sarcomas (1). The leading cause of death is myocar-
dial infarction. WS cells display genomic instability with
chromosomal deletions, elevated rates of homologous re-
combination, prolonged S-phase DNA synthesis and de-
fective telomere maintenance (2). WS is caused by the
loss of function of a single gene (3) that encodes a 1432-
residue protein, Werner protein (WRN) (3,4). WRN is
a member of the RecQ helicase family. RecQ helicases
play important roles in the maintenance of genomic sta-
bility. They act in many DNA metabolic processes, in-
cluding DNA replication, recombination, base excision re-
pair (BER) and transcription (5). DNA helicases of the
RecQ family have a broad amino acid sequence homol-
ogy to the Escherichia coli RecQ helicase. These 3′–5′
DNA helicases unwind a wide variety of potentially re-
combinogenic DNA structures, including four-way junc-
tions, D-loops and G-quadruplex DNA. Humans have
five RecQ homologs, RECQL/RECQL1, BLM/RECQL2,
WRN/RECQL3, RECQL4 and RECQL5 (6). Mutations
in Bloom (BLM) and RECQLQ4 cause Bloom syndrome
and Rothmund–Thomson syndrome, respectively, and sim-
ilarly to the defect in WRN predispose to cancer. WRN is
unique among all RecQ helicases in it displaying both 3′–5′
helicase/adenosine triphosphatase (ATPase) and 3′–5′ ex-
onuclease activities (7).
WRN contains four domains comprising an exonucle-
ase (8), a helicase/ATPase, a RecQ C-terminal (RQC) (9),
a helicase-and-ribonuclease D/C-terminal (10) and a nu-
clear localization signal (NLS, Supplementary Figure S1)
(11). The helicase and RQC domains combine to form the
catalytic core of the protein. The helicase domain has the
RecQ consensus helicase motifs, I, Ia, Ib and II–VI (3).
Motif I, motif II and motif VI are all needed for adeno-
sine triphosphate (ATP) binding and hydrolysis. A part
of motif I known as the Walker A motif is crucial for
ATP binding. The residues of the motif interact with ATP
phosphate groups and with magnesium ions. Mutations
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found in the WRN gene are stop codons, splice site vari-
ants and insertions/deletions that generate frameshift mu-
tations (12). Most mutations lead to the synthesis of C-
terminal truncated protein without the NLS, which can-
not localize to the nucleus (13). Biochemical characteriza-
tion of the human WRN has shown its preferential activity
on various branched DNAs, including bubbles, stem-loops,
forks and Holliday junctions, as well as on RNA-DNA du-
plexes, triplexes and tetraplexes, implying for WRN roles in
DNA replication, recombination and repair (14,15). Post-
translational modifications of WRN modulate its enzy-
matic activity, and thereby could be an important mecha-
nism for the regulation of WRN functions in response to
DNA damage (16,17).
Since mutations in the WRN gene result in so many
aging-like phenotypic changes, it has been reasoned that
polymorphisms in the WRN gene may also contribute to
age-related pathologies in subjects not affected by the syn-
drome, thus influencing aging in the population at large.
One of themost common and intensively studied is the poly-
morphism at amino acid 1367 Cys (TTG)/Arg (CTG). The
1367Arg variant of WRN has been associated with protec-
tion from age-related diseases (18–22), suggesting it has a
functional role.
Lipid peroxidation (LPO), which is significantly in-
creased during inflammation, is implicated in aging as well
as in the pathogenesis of numerous human diseases, includ-
ing atherosclerosis, cancer, diabetes and arthritis (23,24).
One of the major LPO products is 4-hydroxy-2-nonenal
(HNE), a highly reactive ,-unsaturated hydroxyalkenal,
produced by the oxidative degradation of -6 polyunsat-
urated fatty acids of phospholipids, such as linoleic and
arachidonic acids (25). HNE is considered a biomarker
of oxidative stress in pathophysiological processes since
elevated levels of HNE were detected in vivo in several
pathological conditions, including inflammation, and vari-
ous pathologies like liver fibrosis, Alzheimer’s diseases, amy-
otrophic lateral sclerosis, Parkinson’s diseases and Hunt-
ington diseases (4,26–28). Increased levels of HNE-protein
adducts have also been detected in blood plasma from pa-
tients with acute myocardial infarction undergoing coro-
nary angioplasty, a finding indicating a consistent associ-
ation of oxidative stress with acute myocardial infarction
(29). LPO may also occur under physiological conditions.
HNE level in mammals is tissue dependent and increases
with age. HNE concentration in plasma ranges from 0.2 to
2.8 M; however, under conditions of oxidative stress, in-
cluding inflammation, HNEmay accumulate in plasma and
tissues (especially locally in membranes) at concentrations
from 10 to 100 M, or even to milimolar (30–36).
HNE is highly reactive and readily reacts with cellular
macromolecules, such as proteins and DNA. This may lead
to protein carbonylation and formation of exocyclic DNA
adducts, most of which are anticipated to be highly mu-
tagenic. However, HNE reacts much better with proteins
than DNA. Thus, protein modification most likely repre-
sents one of the main mechanisms by which HNE influ-
ences physiological as well as pathological processes (37).
HNE is an electrophile due to its three functional groups
that react with nucleophilic amino acid residues of pro-
teins forming covalent adducts with protein nucleophilic
side chains. HNE reaction with the thiol group of cysteine,
the primary amino-group of lysine or the imidazole group
of histidine leads to formation of stable Michael addition
adducts with a hemiacetal structure (38). The nucleophilic
attack by thiol or amino groups occurs primarily at carbon
3 and, second, at the carbonyl carbon 1. In most cases ad-
duction of HNE to proteins leads to the inhibition of pro-
tein biological activity. For example, we showed previously
that the ATPase activity of Cockayne syndrome group B
protein was abolished after pre-incubation with 200 M
HNE (39). Accordingly, Schwarzer et al. found that forma-
tion of HNE–protein kinase C (PKC) adduct after treat-
ment of human monocytes with 10–100 M HNE totally
inhibited PKC activity (40). Higher doses of HNE (150–300
M) were needed to inactivate 50% activity of microsomal
glucose-6-phosphatase (34). In the case of Hsp72 or Hsp90,
the modification of very sensitive critical thiols by physio-
logically relevant concentrations of HNE (10 and 45 M,
respectively) impaired protein binding and ATPase activity
(41,42). The exposure of purified human SIRT3 to 100 M
HNE resulted in about 75% inhibition (43). Also treatment
of recombinant human Akt2 with 20 or 40 MHNE inhib-
itedAkt2 activity by 30%or 85%, respectively (44). Further-
more, it has been demonstrated that HNE-induced cellular
senescence in leukemic cell lines by inhibiting telomerase
activity (45). Moreover, adduction by HNE made protein
more susceptible to proteolysis by the proteasomal path-
way (46). However, despite overwhelming data showing im-
pairment of catalytic activity of HNE modified proteins, in
some cases formation of HNE-protein adducts can have an
activating effect. Low concentrations of HNE (1–10 M)
stimulated the activity of phosphoinositide-specific phos-
pholipase C (47).
We report here that the WRN protein undergoes HNE
adduction both in vitro and in vivo. The results show that
such post-translational modification of WRN by HNE af-
fects its catalytic activities. Mass spectrometry and in silico
modeling enabled us to identifyHNE-modified amino acids
and determine how they affect WRN conformation and
function. We speculate that accumulation of HNE-WRN
adducts may contribute to the premature aging resembling
the WS phenotype.
MATERIALS AND METHODS
Materials
4-Hydroxy-2-nonenal was synthesized as described (48)
with some modifications done by Marek Komisarski and
Dr. Anna Biela. Monoclonal mouse HNE antibody was
from R&D Systems (Minneapolis, MN, USA), polyclonal
rabbit WRN (H-300), monoclonal mouse WRN (D-6),
normal rabbit and mouse immunoglobulin Gs (IgGs) and
Protein A/G PLUS-Agarose beads were from Santa Cruz
Biotechnology (Dallas, TX, USA). Recombinant histidine-
tagged human WRN protein was purified as described pre-
viously (49).
DNA substrates
DNA oligodeoxynucleotides were synthesized and purified
by Metabion International AG (Martinsried, Germany).
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The sequences of the oligodeoxynucleotides are shown in
Table 1. Template 22–15B or TelY or 43–5over together
with respective top 22–15A or TelX or 32–5over primers
were designed to form 37 or 49 nt fork or 32/43 nt 5′-
overhang partial duplex substrates. Top primers were la-
beled at the 5′-end with T4 polynucleotide kinase (Optik-
inase, Santa Clara, CA, USA) and [ -32P]ATP (GE Health
Sciences) followed by annealing as described previously
(50).
Covalent modification of recombinant WRN with HNE
Covalent modification of humanWRNwas achieved by in-
cubating purified protein (0.1 M) in HW buffer (40 mM
Tris, pH 8, 4 mM MgCl2, 5 mM DTT and 100 g/ml
bovine serum albumin (BSA)) with various concentrations
of HNE. Treatment involved final concentrations of 10, 25,
50, 100, 500 and 1000MofHNE for 10min at 30◦C.These
reactionmixtures were then used tomeasureWRNhelicase,
exonuclease and DNA binding activities or were boiled in
sodium dodecyl sulphate (SDS) loading buffer and applied
to 4–15% SDS-polyacrylamide gel electrophoresis(SDS-
PAGE) followed by transfer to polyvinylidene difluoride
(PVDF) membrane (BIO-RAD, Hercules, CA, USA). Vi-
sualization of adduct formation was monitored by west-
ern blot with polyclonal rabbit anti-HNE antibody. Mem-
branes were then stripped and reprobed for monoclonal
mouse anti-WRN antibody. Immunoblots were visualized
by chemiluminescence using a MultiImage Light Cabinet
and analyzed by associated FluorChem Q Software (Alpha
Innotech Corporation, Santa Clara, CA, USA).
WRN helicase, exonuclease and ATPase activity assay
Helicase reactions were performed at 37◦C in HW buffer.
Reaction mixtures (10 l) contained 1 nM 5′-[32P]-labeled
oligonucleotide-based partial duplex (37 nt fork, 22-
15A/22-15B), 2 mM ATP and 2.5 or 5 nM WRN modi-
fied with different concentrations of HNE. Reactions were
started with the enzyme and terminated after 30 min by
adding 0.5 reaction volumes of SDS/stop solution (2%
SDS, 50mM ethylenediaminetetraacetic acid (EDTA), 30%
glycerol, 0.1% bromophenol blue and 0.1% xylene cyanol).
The reaction products were separated on 8% native PAGE
(acrylamide to bis-acrylamide, 19:1) and run in Tris-borate-
EDTA buffer (90 mM Tris-borate, pH 8.3, 2 mM EDTA)
at 150 V at room temperature. Radiolabeled DNA bands
were visualized by autoradiography using a PhosphorIm-
ager (FLA-7000, FUJIFILM, Tokyo, Japan). Quantitative
analyses of the band shifts were performed using Multi
Gauge software (FUJIFILM). The relative amounts of dis-
placed products were expressed as percentage of totalDNA.
Exonuclease assays were carried out at 37◦C in HW
buffer. Reaction mixtures (10 l) contained 1 nM 5′-[32P]-
labeled oligonucleotide-based partial duplex (49 nt fork,
TelX/TelY or 32/42 nt 5′-overhang, 32-5over/43-5over)
and 5 or 10 nM WRN protein modified with different
concentrations of HNE. When 32/42nt 5′-overhang was
used as a substrate, mixtures were supplemented with 2
mM ATP. Reactions were started with the enzyme and ter-
minated after 30 min by adding 0.5 reaction volumes of
formamide/stop solution (95% formamide, 5 mM EDTA,
0.1% bromophenol blue and 0.1% xylene cyanol). The re-
actions were heat-denatured for 5 min at 90◦C and reaction
products were separated on 15% denaturing PAGE (acry-
lamide to bis-acrylamide, 19:1). Products were visualized
using a PhosphorImager, and quantitifications were per-
formed using the associated software (FUJIFILM). The rel-
ative amounts of cut products were expressed as percentage
of total DNA.
ATPase assays were performed at 37◦C in AW Buffer
(20 mM HEPES–NaOH, pH 7.8, 0.05 mM ATP, 40 g/ml
BSA, 1 mM DTT). Reaction mixtures (10 l) contained 1
Ci [ -32P] ATP, 200 nM oligonucleotide-based partial du-
plex (37 nt fork, 22-15A/22-15B) and 10 nM WRN modi-
fied with different concentrations of HNE. Reactions were
started with the enzyme and stopped after 1 h by the addi-
tion of 5 l of 0.5 M EDTA. ATP hydrolysis was analyzed
on a polyethylenimine-cellulose thin layer chromatography
plate (PEI Cellulose F, Merck, Darmstadt, Germany) de-
veloped in 1 M formic acid and 0.8 M LiCl. Plates were vi-
sualized by PhosphorImaging and quantitification was per-
formed using Multi Gauge software (FUJIFILM).
WRN catalytic activities on DNA templates pre-incubated
with HNE
Radiolabeled oligonucleotide partial duplexes (1 nM 37 nt
fork, 22-15A/22-15B and 1 nM 49 nt fork, TelX/TelY) were
incubated with HNE (0.5 and 1 mM) in HW buffer for 30
min at 37◦C. Templates were then purified using clean-up
columns (Merk Millipore, Darmstadt, Germany) and were
used as substrates forWRNhelicase and exonuclease assays
(5 or 20 nM of protein was used, respectively). The catalytic
reactions were run and analyzed as described above.
Cell culture
Human normal (GM00637) fibroblasts and fibroblasts ob-
tained from patients with WS (AG11395) were purchased
from Coriell Cell Repositories (Camden, NJ, USA). Cells
were maintained in Eagle’s Minimum Essential Medium
withEarle’s salts supplementedwith 10% fetal bovine serum
and non-essential amino acids (Life Technologies, Carls-
bad, CA, USA) in a humidified 5% CO2 atmosphere at
37◦C.
Co-immunoprecipitation (co-IP) assay
Whole cell extracts were prepared from normal (WT) or
WS fibroblasts treated in serum-free medium with 100 M
HNE for 2 h at 37◦C. Cells were harvested and disrupted
by re-suspending in 1 ml of cell extraction buffer (50 mM
Tris-HCl pH 7.4, 150 mMNaCl, 1 mMEDTA, 1 mMNaF,
1 mM Na3VO4, 0.5% NP-40, 0.5% Triton X-100, 0.5 mM
PMSF and 1 mM DTT) supplemented with a protease in-
hibitor cocktail (Complete, Roche, Basel, Switzerland) and
by incubating for 30 min on ice followed by centrifugation
at 16 000 × g for 15 min.
Cell extracts (1 mg each) were pre-cleared with Pro-
tein A/G PLUS-Agarose beads and incubated with 2 g
of polyclonal rabbit anti-WRN antibody or monoclonal
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Table 1. Oligonucleotide sequences for DNA substrates (5′ to 3′)
Oligonucleotide, size Sequence
Helicase primers
22-15A, 37 nt TTTTTTTTTTTTTTTTTAGGGTTAGGGCATGCACTAC
22-15B, 37 nt GTAGTGCATGCCCTAACCCTAATTTTTTTTTTTTTTT
Exonuclease primers
TelX, 49 nt TTTTTTTTTTTTTTTGGTGATGGTGTATTGAGTGGGATGCATGCACTAC
TelY, 49 nt GTAGTGCATGCATCCCACTCAATACACCATCACCTTTTTTTTTTTTTTT
32-5over, 32 nt TGACGTGACGACGATCAGGGTACGTTCAGCAG
43-5over, 43 nt AGTGCAGACTGCTGCTGAACGTACCCTGATCGTCGTCACGTCA
Partial duplex DNA substrates were constructed by annealing appropriate top primer to template oligonucleotide. 22-15A and 22-15B were used to con-
struct the 37 nt fork, TelX and TelY – the 49 nt fork and 32-5over and 43-5over––the 32/43 nt 5′-overhang.
mouse anti-HNE, or 2 g of normal rabbit or mouse IgG
as a negative controls in a total volume of 500 l of cell
extraction buffer for 16 h at 4◦C. Each sample was then
incubated with Protein A/G PLUS-Agarose beads (30 l)
for 4 h at 4◦C. After extensive washing with cell extraction
buffer, bound proteins were eluted by boiling beads in sam-
ple buffer for 5 min and analyzed by western blotting with
mouse anti-HNE or rabbit anti-WRN or mouse anti-WRN
followed by chemiluminescence analysis.
For helicase, exonuclease and ATPase assays with im-
munocomplexes, rabbit IgG or rabbit anti-WRN immuno-
precipitates were washed three times with cell extraction
buffer and two times with HW or AW buffer, followed by
the addition of the radiolabeled DNA substrates. The cat-
alytic reactions were run and analyzed as described above
but incubation times were longer: 1 h for the helicase and
exonuclease activity on fork substrates and 2 h for the AT-
Pase and exonuclease on 5′-overhang.
Electrophoretic mobility shift assay
The binding reaction mixtures (10 l) contained 10 mM
Hepes-KOH, pH 7.8, 1 mM EDTA, 0.5 mM DTT, 50
ng/l BSA, 1 nM of 37 nt 5′-[32P]-labeled 22-15A/22-15B
or 1 nM of 49 nt 5′-[32P]-labeled TelX/TelY and 25 nM
WRN. The mixtures were incubated for 30 min on ice,
after which glycerol was added to final concentration of
25%. Aliquots were removed and analyzed by electrophore-
sis on 4% non-denaturing polyacrylamide gels (80:1 or
37.5:1 acrylamide:bisacrylamide) in buffer containing 20
mM Hepes-KOH pH 7.8, and 0.1 mM EDTA at 100 V for
2 or 3 h, respectively, at 4◦C. The gels were visualized using
a PhosphorImager.
Mass spectrometry
Recombinant human WRN was incubated with increas-
ing concentrations of HNE followed by NaBH4 (5 mM)
reduction at 25◦C for 30 min to stabilize protein adducts.
Samples were digested overnight with trypsin (sequencing
Grade Modified Trypsin–Promega V5111). Peptide mix-
tures were analyzed by LC-MS-MS/MS (liquid chromatog-
raphy coupled to tandem mass spectrometry) using Nano-
Acquity (Waters) LC system and Orbitrap Velos mass spec-
trometer (Thermo Electron Corp., San Jose, CA, USA).
Briefly, peptide mixture was applied to RP-18 pre-column
(nanoACQUITY Symmetry R© C18 – Waters 186003514)
using water containing 0.1% trifluoroacetic acid (TFA) as
mobile phase and then transferred to nano-HPLC RP-18
column (nanoACQUITY BEH C18 – Waters 186003545)
using an acetonitrile gradient (0–30% AcN in 160 min)
in the presence of 0.05% formic acid with the flow rate
of 250 nl/min. Column outlet was directly coupled to the
ion source of the spectrometer working in the regime of
data dependent MS to MS/MS switch. A blank run en-
suring lack of cross-contamination from previous samples
preceded each analysis. Acquired raw data were processed
by Mascot Distiller followed by Mascot Search (Matrix
Science, London, UK, on-site license) against SwissSprot
database (v. 10 2012) restricted to human entries. Search
parameters for precursor and product ions mass tolerance
were 20 ppm and 0.4 Da, respectively; enzyme specificity:
trypsin, missed cleavage sites allowed: 1, fixed modification
of cysteine by carbamidomethylation and variable modi-
fication of lysines carboxymethylation, methionine oxida-
tion and HNE of cysteines, lysines and histidines. Peptides
with Mascot Score exceeding the threshold value corre-
sponding to <5% false positive rate, calculated by Mascot
procedure, and with the Mascot score above 30 were con-
sidered to be positively identified. Peptides with indicated
HNEmodification identified byMascot were manually val-
idated. During fragmentation, the peptide dissociates into
two fragments. Fragments containing the N-terminal part
of the peptides are termed b series ions (singly ‘b’ and dou-
bly ‘b++’ charged), and, respectively, fragments containing
the C-terminal part are named y series ions (singly ‘y’ and
doubly ‘y++’ charged) (51).
Molecular modeling
All simulations were performed using Yasara Structure
package (version 13.4.21, Graz, Austria). Helicase and
RECQ domains of the Werner protein (569 residues corre-
sponding to fragment 521–1089) were modeled by homol-
ogy, basing on four closest templates identified in RCSB
Protein Data Bank (PDB) records, IDs: 1OYW, 2V1X,
1OYY, 2WWY. Three of them, for which re-refinement
was found to improve the structure quality Z-score, were
downloaded from a databank of updated and optimized
X-ray structure models, PDB REDO (www.cmbi.ru.nl/
pdb redo). According to overall quality Z-score, the best
models were built on the basis of 2V1X and 1OYW PDB
records. However, the final hybrid model, which combines
the best parts of top models, was scored higher than the
letters, and thus was further used in the analyses. ADP
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molecule was placed according to known structure of hu-
man RECQ-like DNA helicase (PDB ID: 2V1X). Model of
single-strand DNA bound to WRN was adopted from hu-
man RECQ-like helicase in complex with a DNA substrate
(PDB ID: 2WWY). HNE molecules were attached either
to Lys577 or Cys727 of the WRN hybrid model with the
YAMBER force field, and further subjected to minimiza-
tion (1000 iteration) followed by simulated annealing pro-
cedure in the presence of explicit water molecules. In these
steps coordinates of residues located outside 5A˚ sphere of
HNE were preserved. Finally, the whole system was refined
by 200 ps unrestrained molecular dynamics in NPT ensem-
ble.
RESULTS
Human WRN is a target for covalent modification by HNE
To determine whether HNE covalently binds to WRN pro-
tein, we examined its in vitro adduction to WRN by incu-
bating the mixture of purified recombinant human WRN
(0.1 M) and BSA (1.5 M) with HNE in the concentra-
tion range of 10–1000 M over a 10 min time course at
30◦C. The presence of BSA in the reaction mixture assured
WRN stability throughout the course of HNEmodification
and enzymatic activity assays. The molar ratio of HNE to
WRN/BSA varied from 6- to 600-fold. The reaction prod-
ucts were analyzed by western blot with the use of anti-
HNE antibody. As shown in Figure 1A, upper panel, the
extent of HNE modification of WRN protein increased in
a concentration-dependent manner. Quantification of the
western blots indicated a 5- to 200-fold increase in the level
of HNE-modified proteins compared to the mock-treated
control (Figure 1B). Analysis of the same blot with anti-
WRN antibody showed equal amounts of WRN in each re-
action (Figure 1A, lower panel). These results indicate that
HNE binds to WRN in vitro.
HNE adduction alters the enzymatic activity of the WRN
protein in vitro
It was previously shown that HNE directly affects the ac-
tivity of some DNA repair proteins. Here, we investigated
whether HNE could also affect the catalytic activities of
WRNprotein. First, we focused on the helicase activity. The
DNA substrate used in this assay consisted of a 37 bp par-
tial duplex with 15 unannealed nucleotides (37 nt fork). The
fork substrate was susceptible to WRN unwinding and 37
nt single-stranded products were visible (Figure 1C, lanes
2 and 3). In the presence of 2.5 nM WRN, 79% of 1 nM
substrate was unwound. Under these conditions, we ana-
lyzed WRN unwinding as a function of HNE concentra-
tion. Depending on the concentration used for the modifi-
cation, HNE had different effects on WRN helicase activ-
ity (Figure 1C, lanes 4–13). At a concentration of 25 M,
HNE did not influence the enzyme (Figure 1C, lanes 4–5
andD).WRNmodifiedwith 50MHNEdisplayed slightly
increased helicase activity, which was indicated by slight in-
crease in the percent of unwound substrate (116% compared
to the mock-treated WRN; Figure 1C, lanes 6–7 and D).
When WRN was adducted with higher HNE concentra-
tions (100–1000 M), helicase activity decreased gradually.
Only 48% and 27% of the substrate was unwound by 2.5 nM
WRN, in comparison to control, in the reaction withWRN
pre-treated with 100 and 500 M HNE, respectively (Fig-
ure 1C, lanes 8 and 10 and D). WRN modified with 1000
M HNE did not unwind the 37 nt fork at all (Figure 1C,
lanes 12–13 and D).
The DNA substrate used in the exonuclease assay con-
sisted of a 49 bp partial duplex with 15 unannealed nu-
cleotides (49 nt fork). This fork substrate was susceptible to
WRN degradation and several shorter products were gen-
erated (Figure 1E, lanes 2 and 3). Mock-treated WRN (10
nM) degraded 77% of the 1 nM substrate (Figure 1E, lane
2). Increasing HNE concentration (25–1000 M) used for
WRN modification yielded gradual inhibition of the DNA
substrate cleavage (Figure 1E, lanes 4–13 and F). WRN (10
nM) modified with 25 M HNE displayed a slight reduc-
tion in exonuclease activity (87% of the control activity) but
after adduction with 50, 100 and 500 M HNE only 75%,
42% and 7%, respectively, of 49 nt fork substrate was de-
graded compared to the mock-treated WRN (Figure 1E,
lanes 7, 9 and 11 and F). There was no cleavage by WRN
modified with 1000 M HNE (Figure 1E, lanes 12 and 13
and F).
Next, we investigated whether HNE was able to inacti-
vate the ATPase activity of the WRN protein in vitro. The
DNA substrate used as cofactor in the ATPase assay was a
37 nt fork. Mock-treated WRN (10 nM) in the presence of
200 nM co-factor hydrolyzed 28% of the 1 Ci ATP (Fig-
ure 1G, lane 2). We observed gradual inhibition of ATP hy-
drolysis usingWRN protein pre-treated with HNE, (Figure
1G, lanes 3–7 and H). At 25–100 M HNE, compared to
the mock-treatedWRN, some reduction of ATPase activity
was observed (65% to 60% of ATP underwent hydrolysis).
At 500 MHNE, 46% of ATP was hydrolyzed to inorganic
phosphate and at 1000 MHNE, 21% as compared to con-
trol.
BSA also reacts with HNE and it is possible that if BSA
was not added to the reactions WRN would be even more
sensitive toHNEmodification than reported by above data.
However, our experimental conditions with BSA resemble
more precisely conditions in the cells and tissues (e.g. serum
albumin in blood), where there is a lot of shielding proteins,
which could sequester HNE away from WRN.
It is well established that HNE reacts with DNA much
less efficiently than with proteins, however, in order to ex-
clude the possibility that high concentrations of HNE could
react with the DNA fork substrates and that potential HNE
adduction to the DNA was responsible, at least partially,
for the decreased WRN activities, we performed additional
control experiments using the radiolabeled oligonucleotides
(37 nt fork, 22-15A/22-15B and 49 nt fork, TelX/TelY) pre-
incubated with high HNE concentrations (0.5 and 1 mM).
Supplementary Figure S1 clearly shows that WRN helicase
and exonuclease activities on untreated templates and on
the templates incubated with HNE were very similar. Un-
treated 1 nM 37 nt fork in the presence of 5 nMWRN was
unwound to 92% (Supplementary Figure S1A, lane 2 andB)
and this substrate preincubated with 0.5 and 1 mM HNE
was unwound to 92% and 91%, respectively (Supplemen-
tary Figure S1A, lanes 3 and 4 and B). Untreated 1 nM 49
nt fork in the presence of 20 nMWRN was cleaved to 87%
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Figure 1. Effect of HNE on recombinant WRN. (A) HNE covalently modifies WRN in a concentration-dependent manner. PurifiedWRN in the presence
of BSA was incubated with increasing molar ratios of HNE for 10 min at 30◦C. Samples were boiled in SDS loading buffer, subjected to SDS-PAGE,
blotted and probed for HNE followed by stripping and reprobing for anti-WRN antibodies. (B) Fold increase in WRNmodification from the data shown
in (A). (C) Effect of HNEmodification onWRN helicase activity. PurifiedWRNwas incubated with increasing molar ratios of HNE and enzymatic assays
were performed as described inMaterials andMethods. (D) Percent of control helicase activity from the data shown in (C). (E) Effect of HNEmodification
on WRN exonuclease activity. Purified WRN was incubated with increasing molar ratios of HNE, and enzymatic assays were performed. (F) Percent of
control exonuclease activity from the data shown in (E). (G) Effect of HNEmodification onWRNATPase activity. (H) Percent of control ATPase activity
from the data shown in (G). Mock, control enzymatic activity performed with WRN that has been treated as HNE modified WRN but without HNE.
Lane 14, heat denatured helicase substrate. All data bars are the mean of at least three independent experiments with SDs indicated by error bars. Statistical
analysis occurred via one-way analysis of variance with Tukey’s multiple-comparison test (*P < 0.05; ***P <0.001).
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(Supplementary Figure S1C, lane 2 and D) and this sub-
strate pre-incubated with 0.5 and 1mMHNEwas degraded
to 92% (Supplementary Figure S1A, lane 3 and 4 and B).
These results clearly suggest that the decrease in helicase,
exonuclease and ATPase activities was due to modification
of the WRN protein by HNE. These observations demon-
strate that adduction of WRN by pathologically relevant
concentrations of HNE strongly affects WRN catalytic ac-
tivities and point to the functional significance of thisWRN
modification.
Covalent modification of WRN by HNE in vivo
To determine whether WRN undergoes HNE adduction
in cells, we performed co-IP experiments using cell ex-
tracts prepared from human fibroblasts obtained from ei-
ther an unaffected (WT) or a WS individual. Cells were
mock or HNE pre-treated. The incubation of the extracts
with an antibody against WRN specifically immunoprecip-
itated endogenous WRN from WT but not WS extract, as
expected (Figure 2A, middle panel, lanes 6–8), and also co-
precipitated HNE adducted WRN from WT extract (Fig-
ure 2A, upper panel, lane 7). This result was confirmed by
a reciprocal co-IP experiment, in which antibody to HNE
co-immunoprecipitated endogenous HNE adducted WRN
(Figure 2B, upper panel, lanes 6–7). As expected, there was
no such signal in immunoprecipitate purified from WS cell
extract (Figure 2B, upper panel, lane 8). Control experi-
ments showed that pre-immune IgG did not immunopre-
cipitate WRN or HNE-WRN (Figure 2A, upper and mid-
dle panels, lanes 4–5 and B, upper panel, lanes 4–5). These
results demonstrate that WRN forms a covalent complex
with HNE in vivo.
HNE adduction inhibits helicase, exonuclease and ATPase
activities of WRN in vivo
To investigate the potential consequence of HNE adducted
WRN in cells, we measured the helicase and the exonucle-
ase activities in WRN immunocomplexes purified from hu-
man WT and WRN null fibroblasts, mock or HNE pre-
treated. The washed anti-IgG or anti-WRN immunopre-
cipitates were incubated with radiolabeled DNA substrates,
37 nt fork to assess the helicase activity and two substrates
for the exonuclease activity, 49 nt forked and 32/43 nt 5′-
overhang. The last substrate requires addition of ATP to
be efficiently degraded by WRN. To assess the ATPase ac-
tivity immunocomplexes were incubated with [ -32P] ATP
and 37 nt fork oligodeoxynucleotide as a cofactor. The re-
sults showed that the anti-WRN immunoprecipitates puri-
fied from untreated WT cells efficiently unwound the 37 nt
forked duplex substrate (Figure 3A and E, lanes 3) and de-
graded both the 49 nt fork and the 32/43 nt 5′-overhang
(Figure 3B, C and E, lanes 3). However, it is possible that
other helicases which complex withWRN, e.g. BLM, could
come downwith the immunoprecipitation and contribute to
the observed unwinding activity as well as to its inhibition.
We also observed some degradation in immunocomplexes
purified with control IgG and those obtained from WS cell
extracts with the use of anti-WRN antibody (Figure 3B, C
and E, lanes 1, 2 and 5). However, under these conditions,
there was no detectable helicase or ATPase activity (Fig-
ure 3A–E, lanes 1, 2 and 5). The unwinding, degradation
andATP hydrolysis were strongly inhibited in immunocom-
plexes purified from WT fibroblasts pre-treated with HNE
(Figure 3, lanes 4). The helicase activity was inhibited most
efficiently (only 15% of the substrate was unwound in com-
parison to 51% of mock-treated control) (Figure 3A and E,
lanes 4 and 3, respectively). The 49 nt fork and the 32/43
nt 5′-overhang were cleaved in 25% and 33%, respectively;
whereas in reactions with untreated immunocomplexes they
were cleaved in 64% and 75%, respectively (Figure 3B, C
and E, lanes 4 and 3, respectively). In comparison with the
very efficient inhibition of the helicase activity, the ATPase
wasmuch less inhibited, showing 33%hydrolysis in the pres-
ence of immunocomplexes treated with HNE. In the reac-
tionwithmock-treated ones, the hydrolysis was 50% (Figure
3D and E, lanes 4 and 3, respectively). These results suggest
thatWRN adduction by HNE inside the cell interferes with
the catalytic activities of the enzyme.
HNE modification does not alter the DNA binding affinity
To assess the mechanism by which aldehydic alkylation of
WRN decreases its catalytic activities, a well established
DNA binding assay with a 37 or 49 nt fork duplex sub-
strate was used. As shown in Figure 4, the DNA binding
of unmodified WRN was very slight and no reduction in
the WRN affinity was observed following treatment with
pathologically relevant concentrations of HNE (25–1000
M). These data suggest that the functional effects ofWRN
modification by HNE are not related to decreased WRN
DNA binding affinity.
Identification of HNE adducts on WRN protein
LC-MS/MSwas applied for finemapping of theHNEmod-
ification sites in human recombinant WRN. Analysis of
trypsin digests of WRN resulted in MS peptide sequence
coverage of 81% and revealed 6 HNE adducts (Supplemen-
tary Figure S2). Two of the identified adducts were local-
ized within the ATPase domain, at Lys577 and Cys727. The
remaining four modifications were in the C-terminal part
of the protein, at His1290, Cys1367, Lys1371 and Lys1389
(Figures 5 and 6A and Supplementary Figure S3). Figure
5 displays the MS/MS spectrum of parent ions containing
Lys577 and Cys727, respectively, where relative y and b ions
confirm HNE adducts on WRN. The remaining MS/MS
spectra of the HNE adducted peptides also confirmedmod-
ifications on His1290, Cys1367, Lys1371 and Lys1389 and
are shown in Supplementary Figure S3.
Figure 6B provides a UniProt sequence comparison be-
tween forms of human, murine, horse, chicken and Xeno-
pus laevis WRN (www.uniprot.org). This alignment shows
strong conservation of Lys577, Cys727 and His1290, and
suggests a shared susceptibility to alkylation of those spe-
cific amino acid residues for human, murine, horse, chicken
and X. laevis forms of WRN.
Molecular modeling of HNE adducted WRN
In order to determine the structural consequences follow-
ing HNE adduction of Lys577 and Cys727 and their im-
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Figure 2. WRN is modified by HNE in vivo. Human normal (WT) or WS fibroblasts were pre-treated with 100 M HNE for 2 h. Cell extracts were
prepared and immunoprecipitated with rabbit anti-WRN or mouse anti-HNE antibodies (lanes 6–8, A and B, respectively) or control IgG (lanes 4 and 5,
A and B). The immunoprecipitates were analyzed by SDS-PAGE and western blot with mouse anti-HNE or mouse anti-WRN (A), or rabbit anti-WRN
antibodies (B). Input, 2.5% loaded. Lanes 1, input fromWT cell extract. Lanes 2, the same as lanes 1, but cells were pre-treated with HNE. Lanes 3, Input
from WS cell extract pre-treated with HNE.
pact on WRN function, we performed molecular model-
ing simulations. Based on the available PDB data, we con-
structed a model of the helicase and RQC domains of hu-
manWRN (521–1089 aa, Supplementary Figure S4A). The
model was initially derived as a combination of 20 ho-
mology models built independently on the basis of E. coli
RecQ catalytic core (PDB IDs: 1OYW and 1OYY) and hu-
man RECQL1 (PDB IDs: 2WWY and 2V1X; Supplemen-
tary Figure S4B). Further combination of energyminimiza-
tion and restrained simulated annealing followed by 100 ps
molecular dynamics was used to refine the protein structure
with HNE modified Lys577 and Cys727. According to the
model obtained, the addition of HNE to Lys577 precludes
binding of ATP (ADP) toWRN since the locations of HNE
and ATP overlap (Figure 7A and Supplementary Figure
S4C). The HNE moiety that modifies Lys577 was found to
occupy the ATP-binding site, thus interfering with normal
ATPase and helicase functions. Figure 7B and Supplemen-
tary Figure S4C show peripheral location ofHNE adducted
to Cys727. Inspection of the modeled structures demon-
strates that these modifications (i.e. Lys577 and Cys727) are
not expected to influence the binding ofDNA, which defini-
tively interacts with distant regions of the WRN protein
(Supplementary Figure S4D). Figure 7C and D illustrate
the differences in the conformation of Lys577 and Cys727
as well as in several surrounding amino acid residues (in-
cluding those of the Walker A motif) between native and
aldehyde adductedWRN (amino acids residues are denoted
as blue and green sticks, respectively). HNE addition results
in minor structural differences, with root mean square de-
viation (RMSD) for side-chain heavy atoms of 1.55 A˚. The
RMSD for Lys577 was 1.37 A˚, and for Cys727 equaled 1.24
A˚. For the residues of the Walker A motif RMSD was 1.1
A˚.
To further examine the effects of HNE modification,
molecular surfacemaps with electrostatic potential were ap-
plied. Figure 8 and Supplementary Figure S5 clearly show
differences in molecular surface and electrostatic potentials
of the entire WRN model upon alkylation of Lys577 and
Cys727, which may also affect the function of the enzyme.
Moreover, an entrance site and internal cavity around the
ATP binding pocket seen in native state clearly expanded
uponHNE addition (Figure 8C and D, and Supplementary
Figure S5C and D). Taken together, these data demonstrate
the mechanism of HNE mediated inhibition of WRN he-
licase activity whereby the binding of ATP to the Walker
motif is precluded by steric hindrances with HNE.
DISCUSSION
The maintenance of genome stability is critical for the sup-
pression of cancer and premature aging. Mammalian cells
are continuously exposed to reactive oxygen species, which
are thought to be a major contributor to the aging process.
Previous studies have indicated that the exposure of cells to
even minimal transient stress causes substantial LPO (52).
According to the oxidative theory of aging (53,54), oxidized
lipoproteins may activate inflammatory events, which could
lead to the generation of reactive oxygen species, DNA
damage and mutagenesis. Genomic instability along with
accumulation of DNA damage and cellular senescence is
commonly seen in WS cells (14). Whether oxidative stress
is a pathological factor in WS disease progression remains
an issue of debate. There are many pieces of evidence sug-
gesting such a link. WS cells are sensitive to some agents
introducing oxidative damage to DNA and display a hyper-
oxidation phenotype (55,56). Some features observed inWS
patients may be directly related to a defect in repair of ox-
idative DNA lesions by BER. WRN is considered to be an
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Figure 3. HNE adduction of WRN inhibits its helicase and exonuclease activities in vivo. Human normal (WT) or WS fibroblasts were pre-treated with
HNE and the cell extracts were immunoprecipitated with rabbit anti-WRN antibody or control rabbit IgG. The immunoprecipitates were used in the
measurements of WRN helicase (A), exonuclease (B and C) or ATPase activity (D) as described in Materials and Methods. Representative gels are shown.
(E) Percent of helicase, exonuclease or ATPase activities from the data shown in A–D. Lanes 1, radiolabeled DNA substrate for helicase (A) or exonuclease
(B and C) activity assays were reacted with control IgG immunocomplexes prepared from untreated WT fibroblasts. Lanes 2, the same as lanes 1, but cells
were pre-treated with 100 MHNE for 2 h. Lanes 3, the same as lanes 1, but substrates were reacted with immunocomplexes obtained against anti-WRN
antibody. Lanes 4, the same as lanes 3, but cells were pre-treated with HNE. Lanes 5, the same as lane 4, but immunocomplexes were purified from WS
fibroblasts. Lane 6, heat denatured helicase substrate. All data bars are the mean of three independent experiments with SDs indicated by error bars.
Statistical analysis occurred via Student’s t-test (***P < 0.001).
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Figure 4. Modification ofWRNbyHNE does not change its DNA binding affinity on 22–15A/22–15B 37 nt (A) or TelX/TelY 49 nt partial DNA duplexes
(B). Lane 1, control DNA substrate; lane 2, as 1 but DNA substrate was pre-incubated with mock-treated WRN; lanes 3–7, as 2 but WRN was treated
with HNE at concentration of 25, 50, 100, 500 and 1000 M, respectively. Mock, control enzymatic activity performed with WRN that has been treated
as HNE modified WRN but without HNE.
important player in BER (57,58) and WRN deficient cells
accumulate 8-oxoguanine, a marker of oxidative stress (59).
Our results show one of the possible molecular mecha-
nisms contributing to the WS-like phenotype. We demon-
strate that the WRN protein undergoes HNE adduction
in vitro, but also in living cells (Figures 1A and B and 2).
Such in vitroWRN modification was associated with mod-
ulation of ATP-dependant unwinding activity and abolish-
ment of fork substrate degradation as well as ATP hydrol-
ysis (Figure 1C–H). Significant inhibition occurred only at
high HNE concentrations (100–1000 M) that are rare in
living organisms under physiological conditions. However,
WRNproteinwas incubatedwithHNEonly for 10min. Ex-
periments with the use ofWRN immunocomplexes purified
from HNE treated cells showed impairment of all catalytic
activities with the strongest inhibition observed for the he-
licase (Figure 3). Since LPO products are quite stable in
cells, inhibition of WRN protein and subsequently numer-
ous DNA metabolic processes in aged individuals with en-
hanced LPO, might became appreciable. Current results are
in line with previous data showing that iron-mediated oxi-
dation of WRN protein led to inhibition of its catalytic ac-
tivity (60).Moreover, exposure of cells to hydrogen peroxide
resulted in oxidation of WRN in vivo (60). Taken together,
these findings strongly suggest that oxidative stress/LPO
via WRN inactivation results in premature aging features.
Furthermore, our analysis of the functional effects of HNE
adducts on WRN did not reveal decreased DNA binding
(Figure 4). It was shown that WRN can unwind several
BER intermediates, such as single-strand break intermedi-
ates, and stimulate polymerase  (pol ) strand displace-
ment DNA synthesis via its helicase activity (57). The ex-
onuclease domain of WRN has proofreading activity that
can remove frequent errors made during nucleotide incor-
poration by pol  and thus potentially enhance the fidelity
of BER (61). Significant HNE adduction to WRN might
decrease the BER and contribute to lower fidelity of DNA
repair synthesis.
Utilizing LC-MS/MS analysis, we have identified HNE
adducts to Lys577 and Cys727 of the helicase domain, and
to four amino acid residues in the terminal part of the pro-
tein (Figures 5 and 6 and Supplementary Figure S3). On
the basis of the structural information obtained from the
homology model of the WRN helicase and RQC domains
and molecular modeling simulations, we showed that the
Lys577-HNE adduct is located in the ATP binding pocket
engaged in ATP binding and hydrolysis, necessary for cat-
alytic activities, helicase/ATPase and for ATP-dependent
exonuclease (Figure 7A and Supplementary Figure S4C).
Moreover, we presented predicted changes in local con-
formation after HNE adduction to Lys577 (Figures 7C
and 8A–D and Supplementary Figure S5A–D) and Cys727
(Figures 7D and 8E–H and Supplementary Figure S5E–H),
which could further affect WRN catalytic activities. HNE
adduction could thus prevent binding of ATP in theWalker
motif within the binding pocket ofWRN. It has been shown
previously that mutants in the ATPase domain of WRN
protein exhibited an almost complete inhibition of the AT-
Pase activity and reduced ATP binding in vitro. Moreover,
it has been reported that WRN polymorphism, R834C lo-
cated in the helicase domain, significantly reduced not only
WRN helicase but also exonuclease activity in immunopre-
cipitates from cell extracts of healthy individuals (62). Simi-
lar results were presented in assays with recombinantWRN
protein containing the G574R missense mutation, which
was recently identified in aWS patient. BothWRN helicase
and exonuclease activities were reduced due to decreased
ATP hydrolysis (63). Thus, prevention of ATP binding to
the Walker motif and conformational change after HNE
binding is proposed as a mechanism behind the disturbed
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Figure 5. HNE modified WRN was characterized by LC-MS-MS/MS analysis. (A) Fragmentation spectrum of the DNVAVMATGYGK
peptide––modified at Lys577. (B) Fragmentation spectrum of the NPQITCTGFDRPNLYLEVR peptide––modified at Cys727. During fragmentation,
the peptide dissociates into two fragments. Fragments containing the N-terminal part of the peptides are termed b series ions (singly ‘b’ and doubly ‘b++’
charged), and, respectively, fragments containing the C-terminal part are named y series ions (singly ‘y’ and doubly ‘y++’ charged) (51). Tables represent
a list of theoretical fragment ions calculated by the Mascot program, which served to identify modified peptide (fragment ions found in the spectra are
shadowed). Assignment of dominating peaks from the spectra to the theoretical fragmentation ions definitely confirms the modification.
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Figure 6. HNE modified amino acids identified in WRN. (A) Domain structure of the WRN protein. Positions of the HNE adducted amino acids are
indicated by arrows. Functional domains are indicated below the structure. (B) Sequence alignment of WRN protein fragments (spanning part of the
helicase and the C-terminus) of human, murine, horse, chicken (CHICK) and X. laevis (XENLA) origin. HNE modified amino acids, Lys577, Cys727,
His1290, Cys1367, Lys1371 and Lys1389, are surrounded by red rectangles and indicated by arrows. Walker A motif (571–578) and nuclear localization
sequence (1370–1375) are highlighted in yellow and dark blue rectangles, respectively. The peptides surrounding Lys577 are identically matched for seven
residues toward the N-terminus and three residues toward the C-terminus. Human Lys577, Cys727, His1290, Cys1367, Lys1371 and Lys1389 correspond,
respectively, to murine Lys541, Cys691, His1255, Cys1332, Arg1336 and Lys1354; horse Lys566, Cys716, His1280, Cys1359, Lys1363; chicken Lys556,
Cys706, His1270, Cys1391, His1395 and Asp1438; and X. laevis Lys518, Cys668, His1238, Cys1348, Lys1352 and Thr1387. The picture was prepared with
ClustalX2 (http://www.clustal.org) and visualized by Jalview (http://www.jalview.org).
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Figure 7. Structural changes in the helicase and RQC domains of the WRN protein upon HNE adduction. (A and B) Modeled structure of the WRN
helicase and RQC domains with HNE modifications. Side chains of Lys577 (A) and Cys727 (B), which undergo HNE addition, are denoted in red using
a space-filling model while the ADP residue is shown in magenta. Magnesium ion is marked as a yellow ball. (C and D) Stereo views demonstrating the
changes in local architecture around Lys577 (C) and Cys727 (D) after HNE addition. The unmodified andmodified proteins are denoted in blue and green,
respectively. RMSDLys577 and RMSDCys727 denote the RMSD between unmodified and HNE adducted Lys577 and Cys727, respectively.
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Figure 8. Changes in molecular surface of helicase andRQC domains ofWRNprotein uponHNE adduction. Surface representation ofWRN electrostatic
potential (±25 kT/e, red-negative, blue-positive, gray-neutral) before (A) and after HNE addition to Lys577 (B). A comparison of the vicinity of native (C)
and HNE adducted Lys577 (D) show some changes in molecular surface in the proximity of the ATP (ADP) binding pocket. (E) Surface representation
of helicase and RQC domains of the WRN protein after orthogonal rotation along the Y-axis of 45◦ in relation to structure shown in (A). (F) Surface
representation of helicase and RQC domains of the WRN protein with HNE attached to Cys727. Detailed views of the vicinity of native (G) and modified
(H) Lys727 illustrate changes in charge distribution and reveal surface location of HNE.
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unwinding and ATP-dependent degradation of DNA inter-
mediates. However, stronger inhibition observed for the he-
licase (71%) than for ATPase (34%) could indicate a more
complex mechanism of impaired unwinding than just due
to blocked ATPase activity (Figure 3A, D and E). Molec-
ular surface mapping around the ATP binding pocket re-
vealed substantial changes in pocket structure and acces-
sibility (Figure 8C and D, and Supplementary Figure S5C
and D). These results suggest changed functional dynam-
ics that could be attributed to WRN regulation. However,
we did not determine the mechanism of the inhibited ATP-
independent exonuclease activity on the 49 nt fork sub-
strate (Figures 1E and F and 3B). The possible explana-
tions are (i) that the region of exonuclease domain which
lacked peptide coverage was modified with HNE (35% un-
covered amino acids, Supplementary Figure S2) or (ii) that
conformational shifts caused byHNE alkylation of the heli-
case domain and the C-terminal part of WRN protein were
large enough to influence the conformation of the exonu-
clease domain and affect its function. The latter hypothesis
seems to be supported by (i) structural differences within
the entire helicase and RQC domains following binding of
HNE to Lys577 and Cys727. HNE-WRNminimized struc-
ture revealed some differences in global conformation com-
pared to the native protein, as shown by the RMSD value
of 1.55 A˚. It is also supported by (ii) global differences in
surface electrostatics through the entire helicase and RQC
domains between native and HNE modified WRN. Thus,
one cannot rule out the possibility that even the more dis-
tant parts of the protein could also be affected.
Four of six identified HNE adducts were near the C-
terminal part of WRN, at His1290, Cys1367, Lys1371 and
Lys1389. Interestingly, among them Lys1371 is a part of
NLS (Figure 6 and Supplementary Figure S2). The fact
that the p53-binding domain of WRN resides near its C-
terminus (64), a region eliminated by practically all the
mutations found in Werner’s syndrome patients, points to
the importance of this region in preventing accumulation
of genomic damage and suppressing tumors. According
to the PolyPhenn database on single nucleotide polymor-
phisms (http://genetics.bwh.harvard.edu/pph2/), Cys1367 is
vulnerable to damage. The Cys1367Arg variant is the most
common WRN polymorphism, and comprehensive case–
control study on German population showed that the
Cys1367 variant allele was significantly associated with
breast cancer risk. The risk was even higher in carriers of
two risk alleles A of the p53 variantMspI 1798G>A, which
is completely linked to the 16 bp insertion/duplication of
p53PIN3, responsible for interaction with WRN (18). Our
results are in line with these observations and suggest that
accumulation of HNE modified amino acids at the C-
terminus might interfere with the binding of p53 to WRN,
leading to an attenuated apoptotic function of p53 and en-
hanced cellular senescence, which is characteristic for WS
cells. Moreover, two studies have suggested that the wild-
type Cys1367 allele variant of WRN protein was associ-
ated with myocardial infarction in the Japanese population
(19,20); however, in Caucasians no associations with car-
diovascular disease have been found (65). One association
study has reported a protective effect for heterozygous carri-
ers of the WRNArg1367 variant allele against the develop-
ment of soft tissue sarcomas (21) and type 2 diabetes melli-
tus (22). No significant association of WRN Cys1367Arg
with age-related morbidity, cognitive function, longevity,
coronary artery disease, Alzheimer and atherosclerosis was
found in case–control studies (66–68). Although WRN
Cys1367Arg is located adjacent to the NLS, a previous re-
port has failed to detect any significant difference between
Arg1367 and Cys1367 variants with respect to their nuclear
localization or helicase and helicase-coupled exonuclease
activities (65).
In summary, this study demonstrates the dynamic pro-
cesses associated with HNE adduction to WRN, pointing
to perturbations in DNA metabolism observed in WS. Our
results are in line with the oxidative theory of aging.We pro-
pose that elevated oxidative stress and subsequently WRN
helicase/ATPase and exonuclease deficiency viaHNE post-
translational modification impairs DNA replication and
repair, and that these functional defects are responsible
for premature senescence associated features and diseases.
Further studies on specific interactions of HNE-modified
WRN with various target proteins may provide clues to the
mechanisms responsible for such a global effect of HNE on
various cellular processes.
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